跳转至内容
Merck
CN

HANG2MAG-12K

MILLIPLEX® 人血管生成板2,HANG2MAG-12K

Configurable Human Angiogenesis 19-Plex Panel 2

别名:

Human cancer angiogenesis panel, Luminex angiogenesis panel, Millipore human cancer vascular growth factor panel, Multiplex angiogenic factors kit

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


产品名称

MILLIPLEX® 人血管生成板2,HANG2MAG-12K,

description

Configurable Human Angiogenesis 19-Plex Panel 2

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

accuracy: 88-97%, standard curve range: 137-100,000 pg/mL
(Thrombospondin-2), standard curve range: 137-100,000 pg/mL
(sVEGFR2), standard curve range: 137-100,000 pg/mL
(suPAR), standard curve range: 14-10,000 pg/mL
(sAXL), standard curve range: 14-10,000 pg/mL
(sHER3), standard curve range: 14-10,000 pg/mL
(sVEGFR1), standard curve range: 27-20,000 pg/mL
(sIL-6Rα), standard curve range: 27-20,000 pg/mL
(sPECAM-1), standard curve range: 27-20,000 pg/mL
(sTIE-2), standard curve range: 274-200,000 pg/mL
(Angiostatin), standard curve range: 274-200,000 pg/mL
(sE-Selectin), standard curve range: 274-200,000 pg/mL
(sNeuropilin-1), standard curve range: 41-30,000 pg/mL
(Osteopontin (OPN)), standard curve range: 41-30,000 pg/mL
(sEGFR), standard curve range: 41-30,000 pg/mL
(sHER2), standard curve range: 41-30,000 pg/mL
(sc-Kit/sSCFR), standard curve range: 412-300,000 pg/mL
(sVEGFR3), standard curve range: 69-50,000 pg/mL
(sHGFR), standard curve range: 7-5,000 pg/mL
(PDGF-AB/BB)

technique(s)

multiplexing: suitable

input

cell culture supernatant(s)
plasma

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Angiogenesis, the development of new vascular networks, is a key process in normal growth and development as well as in wound healing, with homeostasis maintained by a delicate balance of angiogenic factors and inhibitors. Consequently, insufficient, or excessive blood vessel growth underlies many diseases, including cardiovascular disease, diabetic ulcers, macular degeneration, and cancer. Angiogenesis plays a significant role in tumor growth and metastasis.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 19 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: Angiostatin, soluble E-Selectin, (sE-Selectin), Osteopontin (OPN), Platelet Derived Growth Factor-AB/BB (PDGF-AB/BB), soluble Platelet Endothelial Cell Adhesion Molecule-1 (sPECAM-1), Thrombospondin-2 (TSP-2), soluble AXL (sAXL), soluble c-Kit/Stem Cell Growth Factor Receptor (sc-Kit/SCFR), soluble Epidermal Growth Factor Receptor (sEGFR)†, soluble Human Epidermal Growth Factor Receptor 2 (sHer2), soluble Human Epidermal Growth Factor Receptor 3 (sHer3), soluble Hepatocyte Growth Factor Receptor/c-Met (sHGFR/c-Met), soluble IL-6Rα, soluble Neuropilin-1 (sNRP-1), soluble Tie-2 (sTie-2), soluble Urokinase-type Plasminogen Activator Receptor (suPAR), soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1), soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2), and soluble Vascular Endothelial Growth Factor Receptor 3 (sVEGFR3)†Antibody against active site results in preferential binding to unbound EGFR.

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

通过在此面板中选择可用的分析物来设计多重试剂盒。

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

法规信息

新产品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

The angiogenesis pathway is complex with many targets to analyze. Simultaneous quantification of multiple markers, with the MILLIPLEX® Human Angiogenesis/Growth Factor Panel 1, saves valuable resources. See how this panel was used to correlate angiogenesis biomarkers with early metastatic progression in NSCLC.

Learn how multiplexing with MILLIPLEX® multiplex assays can help simplify cancer research by measuring multiple circulating biomarkers at once. Find multiplex panels to analyze JAK-STAT, mTOR, MAPK, SAPK, TGFβ signaling pathways, and more.

查看所有相关内容

Sayuri Padayachee et al.
Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria, 37(1), 29-34 (2022-08-11)
A dysregulation of angiogenic mediators has been implicated in HIV infection. Inconsistent data exists on highly active antiretroviral therapy (HAART) usage in pregnancy and its association with PE development. In view of the high prevalence of HIV infection and PE
Luka Roškar et al.
Journal of clinical medicine, 10(4) (2021-03-07)
Preoperative determination of the extent of endometrial cancer (EC) would avoid the complications associated with radical surgery. Screening of patients' plasma biomarkers might enable a more precise diagnosis of EC and a tailored treatment approach. This prospective case-control monocentric pilot
Juan Pablo Hinestrosa et al.
Communications medicine, 2, 29-29 (2022-05-24)
Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage